B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6
Immunic's Promising Pipeline Progress and Stable Financials Justify Buy Rating
Immunic Price Target Announced at $10.00/Share by HC Wainwright & Co.
Immunic Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Optimistic Buy Rating for Immunic Driven by Promising Trials and Market Opportunities for VidoCa
Immunic Analyst Ratings
Immunic Analyst Ratings
Immunic Stock's Popularity Rises With Consistent Buy Ratings From Analysts
Brookline Capital Maintains Immunic(IMUX.US) With Buy Rating, Raises Target Price to $13
Analysts Are Bullish on Top Healthcare Stocks: Bluebird Bio (BLUE), Immunic (IMUX)
B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6
B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6
Buy Rating Affirmed for Immunic, Inc. on Promising MS Drug Developments and Favorable Market Position
Immunic Price Target Announced at $17.00/Share by EF Hutton
Immunic Initiated at Buy by EF Hutton
Immunic Analyst Ratings
Leerink Partners Initiates Immunic(IMUX.US) With Buy Rating, Announces Target Price $5
Piper Sandler Sticks to Their Buy Rating for Immunic (IMUX)
Immunic Initiated at Buy by B. Riley Securities
No Data